Lexaria Bioscience (LXRP) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free LXRP Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | finance.yahoo.comHere's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn SituationApril 16, 2024 | msn.comLexaria gets ethics board okay for oral GLP-1 studyMarch 27, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot StudyMarch 14, 2024 | msn.comLexaria appoints Nelson Cabatuan as CFOMarch 11, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 GrowthFebruary 16, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesFebruary 15, 2024 | msn.comWhy Lexaria Bioscience (LEXX) Shares Are MovingJanuary 16, 2024 | finance.yahoo.comLexaria Unveils Extensive Planned 2024 GLP-1 Study ProgramJanuary 11, 2024 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNovember 30, 2023 | msn.comLEXX: GLP-1s’ Sweet OpportunityNovember 1, 2023 | finance.yahoo.comLexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceOctober 18, 2023 | markets.businessinsider.comLexaria Bioscience’s Growth Prospects: New Licensing Agreement, Advanced Core Pipeline, and Positive Clinical TrialsOctober 13, 2023 | finance.yahoo.comLexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSynAugust 5, 2023 | msn.comLexaria Bioscience (NASDAQ: LEXX) Expands Portfolio in Oral Nicotine Delivery SectorAugust 2, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBDJuly 29, 2023 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine StudyJuly 28, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 28, 2023 | finance.yahoo.comLexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine StudyJuly 19, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch ProductsMay 10, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces 2023 Annual Meeting ResultsMay 10, 2023 | finance.yahoo.comLexaria Announces 2023 Annual Meeting ResultsMay 9, 2023 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Dosing Completed on Human Nicotine StudyMay 9, 2023 | investorplace.comWhy Is Lexaria Bioscience (LEXX) Stock Down 27% Today?May 8, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Clinical Nicotine Study Completes Dosing as PlannedMay 8, 2023 | finance.yahoo.comLexaria’s Human Clinical Nicotine Study Completes Dosing as PlannedApril 25, 2023 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension StudyApril 12, 2023 | theglobeandmail.comLexaria (NASDAQ: LEXX) Revolutionizing Delivery Potential for APIs Using DehydraTECH(TM)February 21, 2023 | yahoo.comLexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBDJanuary 15, 2023 | stockhouse.comAnnual Letter from Lexaria CEO, Chris Bunka and Thorough Strategic Update to All StakeholdersJanuary 13, 2023 | benzinga.comLexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in CanadaDecember 22, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption LevelsDecember 20, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Oral Nicotine Study Begins DosingDecember 20, 2022 | benzinga.comLexaria's Human Oral Nicotine Study Begins DosingNovember 21, 2022 | finance.yahoo.comLexaria Bioscience Turns Focus to Dementia and Diabetes with New StudiesNovember 3, 2022 | proactiveinvestors.comLexaria Bioscience progresses with hypertension and oral nicotine studies using DehydraTECHOctober 31, 2022 | msn.comLEXX: DehydraTECH CBD HYPER-H21-4 ResultsOctober 28, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Clinical Hypertension Study a SuccessSeptember 2, 2022 | apnews.comLexaria Welcomes Dr. Catherine Turkel to its Board of DirectorsAugust 12, 2022 | marketwatch.comTinyGemsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Discusses Biotech Industry Valuation MetricsAugust 10, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for HypertensionAugust 10, 2022 | msn.comLexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension CandidateJuly 27, 2022 | apnews.comLexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse EventsJuly 15, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Human Nicotine Study Nearing Start DateJuly 14, 2022 | apnews.comLexaria To Receive Third Patent Granted in Japan; Submits FDA FilingJuly 14, 2022 | baystreet.caLexaria Flat on Patent News from JapanJuly 13, 2022 | finance.yahoo.comLexaria's Human Nicotine Study Nearing Start DateJune 21, 2022 | marketwatch.comLexaria Bioscience Shares Rise 17% After Two Deals With BevNologyJune 6, 2022 | finance.yahoo.comLexaria Files Pre-IND Meeting Request Letter with U.S. FDAJune 6, 2022 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria Files Pre-IND Meeting Request Letter with U.S. FDAJune 6, 2022 | baystreet.caLexaria Edges up on FDA Deal Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… LXRP Media Mentions By Week LXRP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRP News Sentiment▼0.000.54▲Average Medical News Sentiment LXRP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRP Articles This Week▼00▲LXRP Articles Average Week Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Streamline Health Solutions News Today Poxel News Today Alaunos Therapeutics News Today BioVie News Today Evaxion Biotech A/S News Today NeurAxis News Today NeuroBo Pharmaceuticals News Today Accelerate Diagnostics News Today MEI Pharma News Today Cue Health News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LXRP) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
